Paul Romness
Net worth: 5 M $ as of 2026-05-30
Net worth: 5 M $ as of 2026-05-30
Paul A. Romness is the founder of OS Therapies, Inc. since 2018, holding the title of Chairman, President & Chief Executive Officer.
Former positions include Director-State Government Affairs at Amgen, Inc. from 2005 to 2008, Vice President-Government Affairs & Public Policy at Boehringer Ingelheim GmbH from 2008 to 2014, and Principal at PR Strategies from 2005 to 2008.
Education includes an undergraduate degree from American University and a graduate degree from Milken Institute School of Public Health.
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2026-01-21 | 2,473,000 ( 5.55% ) | 5 M $ | 2026-05-30 |
| Companies | Position | Start |
|---|---|---|
| OS THERAPIES INCORPORATED | Chief Executive Officer | 2018-04-11 |
| Companies | Position | End |
|---|---|---|
Boehringer Ingelheim GmbH
Boehringer Ingelheim GmbH Pharmaceuticals: MajorHealth Technology Manufactures and wholesales animal health & pharmaceutical products | General Counsel | 2013-12-31 |
| AMGEN INC. | General Counsel | 2008-02-29 |
PR Strategies | Corporate Officer/Principal | 2008-02-29 |
Active
Inactive
Listed companies
Private companies
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
| Private companies | 6 |
|---|---|
Amgen, Inc.
Amgen, Inc. BiotechnologyHealth Technology Discovers, develops, manufactures and delivers human therapeutics | Health Technology |
Boehringer Ingelheim GmbH
Boehringer Ingelheim GmbH Pharmaceuticals: MajorHealth Technology Manufactures and wholesales animal health & pharmaceutical products | Health Technology |
American University
American University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Milken Institute School of Public Health
Milken Institute School of Public Health Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
OS Therapies, Inc.
OS Therapies, Inc. BiotechnologyHealth Technology Operates as a clinical stage therapeutic company engages in development and commercialization of treatments for osteosarcoma | Health Technology |
PR Strategies |
Select your edition
All financial news and data tailored to specific country editions